Locéryl is generally used as a specialized topical antifungal medication primarily within the therapeutic domain of dermatology and podiatry to address fungal infections that create noticeable physiological strain on the nail structure.

The primary therapeutic application is the management of onychomycosis—the medical term for nail fungus. It is commonly used in conditions where the nail plate is infected by common pathogens, including dermatophytes, yeasts (such as Candida), and various molds. The medication is considered relevant in clinical settings marked by persistent, chronic nail infections, as it is applied in addressing the fungal elements. This provides supportive relief that helps address the infectious process.

Symptomatic Relief and Nail Structural Support

Locéryl is applied to help manage the pronounced, distressing symptomatic manifestations of the infection. This includes addressing the cluster of symptoms associated with pathological nail deformation and aesthetic deterioration: marked nail thickening (hypertrophy), a brittle or crumbling nail texture, and visible discoloration. By addressing the active fungus, the medicine supports the process of managing the physical symptoms, offering a practical benefit that contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

“The primary goal of this localized therapy is to manage the active infection and support the growth of a clear nail structure.”

The medication is commonly used in conditions where the infection is categorized as mild to moderate, affecting a limited portion of the nail structure. This localized approach is particularly relevant in situations where patients require an therapeutic intervention and is used in contexts involving localized application.

---

Quick Fact: Relief for Structural Nail Dystrophy Locéryl is commonly used to help manage the visual and physical disruption caused by fungal infection, including thickening and discoloration that interfere with daily functioning.

Who Can and Cannot Use Locéryl?

Locéryl's population eligibility is strictly defined by regulatory health authorities, focusing on patient age, physiological status, and known allergies. Use is established and permitted for the general adult population (18 years and older).

Eligibility Scope	Status according to Regulatory Documents
Contraindications	Use is absolutely contraindicated in patients with known hypersensitivity or allergy to amorolfine or any of the inactive excipients.
Pediatric Use	Use is Not Recommended in children and adolescents under 18 years due to the lack of sufficient clinical safety and efficacy data.
Pregnancy/Lactation	Use should be avoided during pregnancy and breastfeeding, as clinical experience is limited and the potential risk is unknown.

Condition-Specific Rules	Regulatory Statement
Severe Infection	Monotherapy is not suitable for severe onychomycosis affecting more than two-thirds of the nail plate.
Organ Impairment	No specific contraindications or dose adjustments are formally stated for use in patients with hepatic or renal impairment.

Official regulatory documents use these defined classifications to ensure the medicine is restricted to populations where its safety and suitability have been formally assessed.

The official regulatory profile for Locéryl (Amorolfine medicated nail lacquer) is defined by its topical application and negligible systemic absorption, resulting in a distinct absence of documented systemic drug-drug interactions. Regulatory labels state there are no known interactions with other co-administered medicinal products, and no metabolic (CYP), transporter, or pharmacodynamic interaction studies have been performed. Consequently, no drug combinations are classified as contraindicated due to systemic pharmacological conflict. The documented constraints are centered on maintaining the integrity of the medicated lacquer on the nail surface.

Property	Official Regulatory Statement
Systemic Drug Interactions	None known or documented with other medicinal products.
Timing Separation Rule	Cosmetic nail varnish application requires a separation of at least 10 minutes after the lacquer has dried.
Product Prohibition	The use of artificial nails is officially prohibited on the treated nail during therapy.
Substance Restriction	When exposed to organic solvents (such as thinners or white spirit), impermeable gloves must be worn to prevent the physical removal of the medicated lacquer.

Interaction classifications are based on Product/Substance Physical Interference with the drug's reservoir rather than systemic pharmacological conflict. This profile confirms the treatment's localized scope, where adherence to procedural and product-based constraints is the primary focus of the regulatory interaction section. This approach is consistent across major regulatory authorities due to the minimal systemic drug exposure.

The action of Locéryl, containing Amorolfine, is strictly defined by its targeted interference with the fungal pathogen's essential architecture. The drug initiates its action by acting as an inhibitor of two crucial enzymes in the fungal cell: Delta14 reductase and Delta7-Delta8 isomerase. These enzymes are essential components of the ergosterol biosynthesis pathway. By blocking the activity of these specific biological targets, Amorolfine prevents the final, necessary conversion steps required to create ergosterol, an essential structural lipid of the fungal cell membrane.

---

The enzymatic blockade triggers a cascade that results in membrane structural compromise. This process causes two effects: a severe depletion of ergosterol and the subsequent, toxic accumulation of atypical sterols (such as ignosterol) within the fungal cell . This profound alteration in membrane composition destroys its structural integrity, leading to both the halting of fungal growth (fungistasis) and the outright death of the cell (fungicidal action), a process consistent with pathogen inactivation.

---

Amorolfine's mechanism is physiologically limited to the application site; due to negligible systemic absorption, it is irrelevant for treating internal infections. However, the drug is engineered to establish an active drug reservoir within the dense nail keratin. This mechanism ensures that high, fungicidal concentrations are maintained continuously at the site of activity, supporting continuous enzyme inhibition.

Administration Instructions for Locéryl (Amorolfine 5% Nail Lacquer)

The administration of Locéryl is strictly topical to the affected nail(s) and is governed by a specific preparation and application procedure.

Administration Scope	Detail
Route of Administration	Topical (on affected nails)
Official Dosing	Apply once weekly to the affected finger or toe nails. Twice weekly application may be considered in certain cases.
Preparation	Before the initial application, and before each repeat application, the affected nail areas must be filed down thoroughly using the provided nail file. The nail surface should then be cleansed and degreased using a cleaning pad.
Special Conditions	Nail files used for affected nails must not be used on healthy nails. When handling organic solvents (e.g., thinners), impermeable gloves must be worn to protect the lacquer.
Age-Specific Use	There are no specific dosage recommendations for use in either elderly patients or the paediatric population, the latter due to a lack of clinical experience.
Missed Dose	Treatment must be continued without interruption until the nail is regenerated and the affected areas are finally cured, which typically takes six months for fingernails and nine to twelve months for toenails.

Procedural Sequence

1. File down the affected nail surface and cleanse/degrease with a cleaning pad.
2. Dip the reusable applicator into the lacquer (do not wipe the excess on the bottle neck).
3. Apply the lacquer to the entire surface of the affected nail.
4. Allow the lacquer to dry.
5. Clean the applicator with the same cleaning pad used for nail cleaning, and tightly close the bottle.

This protocol outlines a prolonged, continuous regimen essential for managing onychomycosis, emphasizing meticulous nail preparation and hygiene to ensure effective application of the topical medicine.

Research Evidence / Overview of Studies for Locéryl

This overview focuses exclusively on the published research that has evaluated the clinical use of Amorolfine nail lacquer, as summarized in scientific and regulatory literature. The evidence is presented descriptively, without offering interpretation, clinical guidance, or treatment recommendations.

---

Evidence for Use in Fungal Nail Infections (Onychomycosis)

The research landscape was evaluated in Randomized Controlled Trials (RCTs) exploring the use of this treatment. These trials was studied for its use as a single topical treatment for conditions characterized by mild-to-moderate fungal nail infections in adults. These trials research examined specific endpoints, including Mycological Cure (a lab finding related to the absence of fungus in tests) and Clinical Cure (an outcome related to the visual appearance of the nail). The research so far suggests that findings were mixed, with some trials reporting measurements of clearance while others comparing the lacquer against a non-medicated control reported similar outcomes in the observed populations.

The RCTs typically monitored responses over defined time intervals, usually 9 to 12 months, which research describes as the time needed for nail growth. These studies help show what has been observed so far regarding how the nail changes when only topical treatments are applied in studies examining patient-reported experiences.

Comparative Studies with Oral and Topical Treatments

Studies have also explored how this topical treatment was evaluated in comparison to a placebo or other active agents. Specifically, some trials and meta-analyses research examined the use of the topical lacquer in combination with oral antifungal medications. These combination studies often involved patients whose conditions were marked by disease severity or where the infection was more severe, affecting deeper parts of the nail. The findings describe patterns observed in the studies, reporting that the addition of the topical lacquer to an oral regimen was associated with differences in the percentage of patients achieving mycological clearance, compared to the oral treatment used alone.

These comparative studies contribute to the broader evidence landscape by showing how the treatment was evaluated in different severity levels and against standard treatments. However, direct, head-to-head comparative evidence against some other topical antifungals is limited.

Key Studies & References

1. Nail acidification vs. amorolfine in the local management of onychomycosis: a comparative, prospective, randomized, blind trial

Common questions about Locéryl (FAQ)

Q: Is Locéryl used for all types of nail fungus?

According to official product information, the active ingredient in Locéryl is studied and indicated for use against a broad spectrum of fungi that cause nail infections. This includes common types such as dermatophytes, yeasts, and non-dermatophyte molds. This classification is consistent with its intended use against a wide range of fungal pathogens.

Q: Does Locéryl contain any common allergens?

The medicine is strictly contraindicated for individuals who have a known allergy or hypersensitivity to the active ingredient, amorolfine, or any of its inactive components (excipients). The excipients are identified in the product’s composition list. Use is contraindicated if there is a known hypersensitivity to the active substance or any of these components.

Q: Are there any other names for the active ingredient in Locéryl?

The active substance in Locéryl is amorolfine (as hydrochloride). While Locéryl is the brand name, the ingredient is also known simply as amorolfine or may be referred to by slightly different spellings, such as amorolfin, in various pharmaceutical references globally.

Q: Is Locéryl available over the counter or is a prescription required?

The availability of Locéryl is determined by local regulatory bodies and varies internationally. In some countries, it is classified as a prescription-only medicine, requiring a healthcare provider's authorization. In other areas, such as the UK and Australia, it may be available for sale over the counter.

Q: How does Locéryl compare to other common nail treatments?

Research studies have evaluated this topical treatment by comparing it to a non-medicated control (placebo) and also by using it in combination with oral antifungal treatments. Official information indicates that the topical lacquer is designed to create a long-lasting drug reservoir within the nail to maintain high concentrations of the medication at the site of infection.

Q: Can Locéryl be used by people with diabetes?

Regulatory documents indicate that due to the topical administration and negligible systemic absorption of the active ingredient, the medicine's action is understood to be highly localized. There are no specific contraindications or dose adjustments formally stated in the label for patients with conditions such as kidney or liver impairment.

Q: Is there a generic version of Locéryl?

Yes, the active ingredient, amorolfine hydrochloride 5% nail lacquer, is marketed by various manufacturers. Products containing the same active ingredient are available under different brand names and may be referred to as a generic version in specific international markets where they are registered.

Q: Does Locéryl interact with any common vitamins or supplements?

Official regulatory labels state there are no known systemic interactions documented with other medicinal products. Because systemic absorption is negligible, the treatment is not associated with systemic interactions with vitamins or supplements.

Q: Is it okay to use Locéryl if I have damaged skin around the nail?

The product is strictly for topical use on the affected nail surface. Localized reactions, such as mild burning or itching of the skin immediately surrounding the nail, have been reported. Administration instructions are designed to limit exposure to surrounding healthy skin, eyes, and mucous membranes.

Q: Is the active ingredient in Locéryl related to other antifungal medicines?

The active ingredient, amorolfine, is classified pharmacologically as a morpholine derivative antifungal agent. This places it in a distinct chemical class from other common antifungal medicines, such as the azoles or allylamines. It is designated by health authorities as an antifungal for topical use.

Q: Can Locéryl affect my liver function?

Since Locéryl is a topical medicine with negligible systemic absorption, it is not associated with systemic effects. The official guidance does not state specific dose adjustments or contraindications for use in patients with pre-existing liver impairment.

Q: Are there any restrictions on working or driving while using Locéryl?

The product is applied only to the nails, and the active ingredient is absorbed in minimal amounts into the rest of the body. Because of this negligible systemic exposure, official product information indicates that no effects on the ability to drive or use machinery are anticipated or documented.

Q: Can Locéryl be used if the fungus has spread to multiple nails?

Regulatory guidelines state that the lacquer used as a monotherapy is considered not suitable for treating severe onychomycosis. Severity is defined as infection affecting more than two-thirds of the nail plate, regardless of whether the infection is present on one or multiple nails.

Q: Is it safe to get the Locéryl product on the surrounding healthy skin?

The product is intended only for application to the affected nail surface. Adverse reactions reported are predominantly localized application-site reactions, such as temporary burning or itching.

Q: What happens if I stop using Locéryl before the recommended time?

Treatment with Locéryl is defined as a prolonged, continuous regimen that must be maintained until the nail is fully regenerated and the infection is cured. Stopping treatment prematurely, before the recommended 6 to 12 months, may prevent the achievement of the documented cure endpoint.

Q: Is there information on how Locéryl is excreted from the body?

Official information emphasizes that the drug rapidly penetrates the nail to form a local drug reservoir, and systemic absorption is negligible. Detailed information on systemic pharmacokinetics or excretion routes is not documented in the official regulatory information, which is consistent with the product's negligible systemic absorption.

Q: Can I expose my nails to water or soaps after applying Locéryl?

Regulatory constraints are primarily focused on maintaining the physical integrity of the lacquer. Specific warnings require using impermeable gloves when handling organic solvents (such as paint thinners). There are no specific warnings issued regarding normal exposure to water or soap after the lacquer has fully dried.

How to Store and Dispose of Locéryl

Locéryl (amorolfine) nail lacquer must be stored and handled according to specific regulatory requirements to ensure its stability and safety. The medicine must be kept out of the sight and reach of children.

Storage Requirements

• Temperature and Protection: Store the product below 30°C and protect it from heat. Because the lacquer is flammable, it must be kept away from fire and naked flames and should not be used near ignition sources.
• Container Integrity: The bottle must be kept tightly closed after each use to prevent deterioration. Do not use the medicine after the expiry date.

Disposal Instructions

• Waste Handling: Do not dispose of the medicine via wastewater or household waste. Ask a pharmacist for instructions on how to properly discard any unused or expired product according to local requirements. Used cleaning swabs are flammable and must also be disposed of carefully.